J Breast Cancer.  2019 Jun;22(2):210-218. 10.4048/jbc.2019.22.e27.

The Correlation between IL-1β-C31T Gene Polymorphism and Susceptibility to Breast Cancer

• Eras N
• Daloglu FT
• Çolak T
• Guler M
• Akbas E

• KMID: 2450116
• DOI: http://doi.org/10.4048/jbc.2019.22.e27

Abstract

PURPOSE
Interleukin-1 beta (IL-1β), a pro-inflammatory cytokine, has been shown to influence breast cancer susceptibility. The relationship between its risk of breast cancer and IL-1β-C31T polymorphism has been demonstrated, but the results remain controversial. Therefore, our study aimed to investigate the correlation between the IL-1β-C31T gene polymorphism and susceptibility to breast cancer.
METHODS
The genotype frequencies of IL-1β-C31T polymorphism were compared between 204 breast cancer cases and 210 controls using polymerase chain reaction and restriction fragment length polymorphism techinques. Further multivariate binary logistic regression analyses were used to assess the association between IL-1β-C31T polymorphism and breast cancer risk.
RESULTS
The frequency of the T allele of IL-1β-C31T polymorphism in breast cancer cases was significantly higher than that in the controls (56.1% vs. 47.9%). The frequencies of genotypes CC, CT, and TT in the cases were 22.1%, 43.6%, and 34.3%, respectively, while in the control group they were 24.3%, 55.7%, and 20.0%, respectively. There was a significant difference between the prevalence of TT genotype in the 2 groups (adjusted odds ratio [OR], 2.06; 95% confidence interval [CI], 1.16-3.66; p"‰ ="‰ 0.014). Breast cancer risk increased in women with TT genotype, body mass index (BMI) ≥ 25 kg/m2 (OR, 2.19; 95% CI, 1.09-4.36), late age at first birth (OR, 2.43; 95% CI, 1.29-4.56), postmenopausal status (OR, 3.15; 95% CI, 1.39-7.16), and negative smoking history (OR, 2.52; 95% CI, 1.32-4.82). Furthermore, increase in breast cancer risk among women diagnosed with invasive ductal carcinoma was associated with CT/TT genotypes (OR, 2.82; 95% CI, 1.38-5.76).
CONCLUSION
The IL-1β-C31T polymorphism affects breast cancer susceptibility, especially in women with late age at first birth, high BMI, postmenopausal status, negative smoking history, and invasive ductal carcinoma. Our study adds to the evidence about the importance of IL-1β-C31T polymorphism in breast cancer susceptibility.

Keyword

Breast neoplasms; Genetic susceptibility; Interleukin-1beta; Polymorphism, genetic

MeSH Terms

Alleles
Birth Order
Body Mass Index
Breast Neoplasms*
Breast*
Carcinoma, Ductal
Female
Genetic Predisposition to Disease
Genotype
Humans
Interleukin-1beta
Logistic Models
Odds Ratio
Polymerase Chain Reaction
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
Prevalence
Smoke
Smoking
Interleukin-1beta
Smoke

Reference

1. Rajendran P, Chen YF, Chen YF, Chung LC, Tamilselvi S, Shen CY, et al. The multifaceted link between inflammation and human diseases. J Cell Physiol. 2018; 233:6458–6471.

2. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2012; 2:98.

3. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013; 39:1003–1018.

4. Webb AC, Collins KL, Auron PE, Eddy RL, Nakai H, Byers MG, et al. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res. 1986; 5:77–85.

5. Xu J, Yin Z, Cao S, Gao W, Liu L, Yin Y, et al. Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One. 2013; 8:e63654.

6. Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015; 35:1–16.

7. Perrier S, Caldefie-Chézet F, Vasson MP. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett. 2009; 583:259–265.

8. Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desai SB, et al. Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. Int J Oncol. 1999; 15:1251–1254.

9. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000; 18:293–302.

10. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, et al. Expression of interleukin-1beta in human breast carcinoma. Cancer. 1997; 80:421–434.

11. Lee YH, Song GG. A meta-analysis of the association between CTLA-4 +49 A/G, -318 C/T, and IL-1 polymorphisms and susceptibility to cervical cancer. Neoplasma. 2014; 61:481–490.

12. Chen B, Luo MX, Zhou X, Lv Y, Su GQ. Correlation between interleukin-1β-511 C/T polymorphism and gastric cancer in Chinese populations: a meta-analysis. Med Sci Monit. 2016; 22:1742–1750.

13. Wang F, Zhang Y, Wang S, Zhang Y, Wu D, Zhang C, et al. IL1 genes polymorphism and the risk of renal cell carcinoma in Chinese Han population. Oncotarget. 2017; 8:56021–56029.

14. Xiao D, Zhang SM, Li X, Yin JY, Gong WJ, Zheng Y, et al. IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese type 2 diabetes mellitus patients. Pharmacogenomics. 2015; 16:1621–1629.

15. Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, Molina MÁ, Robles AI, Villar E, et al. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surg Oncol. 2017; 26:278–285.

16. Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer. 2004; 109:353–356.

17. Tak KH, Yu GI, Lee MY, Shin DH. Association between polymorphisms of interleukin 1 family genes and hepatocellular carcinoma. Med Sci Monit. 2018; 24:3488–3495.

18. He Y, Liang X, Meng C, Shao Z, Gao Y, Wu Q, et al. Genetic polymorphisms of interleukin-1 beta and osteosarcoma risk. Int Orthop. 2014; 38:1671–1676.

19. Ito LS, Iwata H, Hamajima N, Saito T, Matsuo K, Mizutani M, et al. Significant reduction in breast cancer risk for Japanese women with interleukin 1B -31 CT/TT relative to CC genotype. Jpn J Clin Oncol. 2002; 32:398–402.

20. Akisik E, Dalay N. Functional polymorphism of thymidylate synthase, but not of the COMT and IL-1B genes, is associated with breast cancer. J Clin Lab Anal. 2007; 21:97–102.

21. Liu X, Wang Z, Yu J, Lei G, Wang S. Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010; 124:821–825.

22. Liu J, Zhai X, Jin G, Hu Z, Wang S, Wang X, et al. Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. Int J Cancer. 2006; 118:2554–2558.

23. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res. 2000; 91:865–868.

24. Lee KM, Park SK, Hamajima N, Tajima K, Choi JY, Noh DY, et al. Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women. Breast Cancer Res Treat. 2006; 96:197–202.

25. Kantono M, Guo B. Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol. 2017; 8:1132.

26. Idris A, Ghazali NB, Koh D. Interleukin 1β-A potential salivary biomarker for cancer progression? Biomark Cancer. 2015; 7:25–29.

27. Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, et al. IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. Oncotarget. 2015; 6:29034–29047.

28. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007; 9:R15.

29. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, et al. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol Rep. 1999; 6:65–70.

30. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol. 1990; 162:502–514.